Global Cancer Biologics Market 2019-2023
About this market
The rising global incidences of cancer are likely to impact the market’s growth during the forecast period. Increasing prevalence of environmental factors including tobacco smoking and pollution and changing dietary patterns are expected to contribute directly to the increased global incidences of cancer. Such rising incidences of this condition will eventually contribute to the cancer biologics market growth during the forecast period. Technavio’s analysts have predicted that the cancer biologics market will register a CAGR of over 11% by 2023.
The rising global incidence of cancer
The major etiological factors leading to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer.
Patient expiry of major cancer biologics
The emergence of biosimilars due to patent expiration of biologics hinder the market growth, despite the increased incidence of cancer during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the cancer biologics market during 2019-2023, view our report.
The market appears to be highly concentrated with the presence of a few market players. Manufacturers in the global cancer biologics market are entering into strategic collaborations to develop or commercialize biologics indicated for the treatment of various types of cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Global Cancer biologics Market 2019-2023
Technavio recognizes the following companies as the key players in the global cancer biologics market: Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the rise in strategic collaborations.”
According to the report, one of the major drivers for this market is the robust pipeline and new drug approvals.
Further, the report states that one of the major factors hindering the growth of this market is the late diagnosis and poor survival of patients with cancer.
Amgen Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyF. Hoffmann-La Roche LtdMerck & Co., Inc.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook